Tekla Capital Management LLC Intellia Therapeutics, Inc. Transaction History

Tekla Capital Management LLC

$2.53 Billion
Q2 2023

A detailed history of Tekla Capital Management LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Tekla Capital Management LLC holds 154,269 shares of NTLA stock, worth $1.76 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares

154,269

Previous 154,269 -0.0%

Holding current value

$1.76 Million

Previous $5.75 Million 9.43%

% of portfolio

0.25%

Previous 0.22%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	BUY	$53.92 - $71.7 $5.18 Million - $6.89 Million	96,089 Added 165.16%	154,269 $8.63 Million
Q2 2021 Aug 13, 2021	BUY	$60.88 - $161.91 $304,400 - $809,550	5,000 Added 9.4%	58,180 $9.42 Million
Q1 2021 May 14, 2021	BUY	$46.59 - $83.68 $2.48 Million - $4.45 Million	53,180 New	53,180 $4.27 Million
Q3 2020 Nov 13, 2020	SELL	$17.47 - $24.93 $961,723 - $1.37 Million	-55,050 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$13.07 - $18.51 $1.24 Million - $1.76 Million	-95,240 Reduced 63.37%	55,050 $735,000
Q4 2018 Feb 13, 2019	BUY	$11.39 - $27.13 $929,640 - $2.21 Million	81,619 Added 118.86%	150,290 $2.05 Million
Q3 2018 Nov 13, 2018	SELL	$25.78 - $32.6 $2.54 Million - $3.22 Million	-98,710 Reduced 58.97%	68,671 $1.97 Million
Q1 2018 May 14, 2018	BUY	$19.43 - $34.95 $3.25 Million - $5.85 Million	167,381 New	167,381 $3.53 Million
Q3 2017 Nov 13, 2017	SELL	$15.16 - $25.75 $424,480 - $721,000	-28,000 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	28,000	28,000 $448,000

Others Institutions Holding NTLA

# of Institutions

314

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $867M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.

Account

Tekla Capital Management LLC Intellia Therapeutics, Inc. Transaction History